Non-Small Cell Lung Cancer (NSCLC)

Stage III Met - IV 2nd Line

Failed Therapy

ALK +
- EGFR/HER2 Mutation, Untreated CNS Mets
  - VAR0084 Phase I/II Anti-Tumor Activity of Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer (NSCLC)
    - PI: Neal Adapimmune Ltd
  - LUN0062 Phase II/III Regorafenib in Combo w/ Oral Methotrexate in KRAS Mutated Non-Small Cell Lung Cancer (NSCLC)
    - PI: Padda Stanford
  - LUN0085 Phase I AZD9291 & Necitumumab in EGFR-Mutant NSCLC After Progression on Previous EGFR TKI
    - PI: Padda NCIC

KRAS+
- Failed EGFR or ALK Inhibitor
  - TK1 1st/2nd Generation
  - LUN0080 Phase I Afatinib & Necitumumab in EGFR Mutation+ NSCLC w/ 1st / 3rd Gen EGFR TKIs Acquired Resistance
    - PI: Padda EpicentRx, Inc
  - TK1 1st/3rd Generation
  - LUN0083 Phase III/II AC0010MA Previously Treated EGFRmut & Acquired T790M Mutation Non-Small Cell Lung Cancer (NSCLC)
    - PI: Wakelee ACEA Bioscience
  - LUN0085 Phase I AZD9291 & Necitumumab in EGFR-Mutant NSCLC After Progression on Previous EGFR TKI
    - PI: Padda NCIC

Failed EGF/ Resistant to TK1 inhibitors

Mesothelin +
- LUN0084 Phase II RRx-001 in SCLC / NSCLC / Neuroendocrine Carcinoma or Ovarian Cancer (Including MIMMT)
  - PI: Padda Stanford
  - VAR0195 Phase Ib Anetumab Ravtansine (BAY 94-9363) in Mesothelin Expressing Advanced Serous Malignancies
    - PI: Neal Adapimmune Ltd
  - MAGE-A10

Failed Platinum Chemo or EGFR/ALK/R0S1 Inhibitor
- LUN0078 Screening for Tumor Antigen Expression Profiling & HLA Typing in Solid & Hematological Malignancies
  - PI: Neal Adapimmune Ltd

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu